UBS Sticks to Its Buy Rating for Softcare Limited (2698)

UBS sticks with its Buy rating on Softcare Limited, signaling continued confidence in the company’s outlook. In a note released on May 27, UBS analyst Charles Eden reaffirmed Softcare’s Buy rating and set a price target of HK$42.20. Softcare’s shares closed the prior session at HK$26.12, illustrating a sizable gap to the target that could attract further investor attention if growth catalysts emerge. TipRanks data show Eden ranks 10,094th out of 12,224 analysts, while Softcare as a whole carries an analyst consensus of Strong Buy with a HK$39.42 price target consensus, signaling a broadly constructive view among street analysts. The report contributes to a broader narrative about Softcare’s potential amid market volatility, highlighting UBS’s willingness to back the stock at a significantly higher level than current prices. While the article does not disclose Softcare’s earnings figures or strategic milestones, the gap between HK$26.12 and the HK$42.20 target implies upside if execution aligns with expectations. The combination of UBS’s stance and the street’s Strong Buy consensus suggests Softcare could deliver meaningful returns for investors who look beyond near-term price action, reinforcing attention on the stock despite limited detail in the piece.